Effects of captopril treatment versus placebo on renal function in type 2 diabetic patients with microalbuminuria: a long-term study

1994 ◽  
Vol 72 (12) ◽  
pp. 961-966 ◽  
Author(s):  
M. Capek ◽  
C. Schnack ◽  
B. Ludvik ◽  
A. Kautzky-Willer ◽  
M. Banyai ◽  
...  
Keyword(s):  
Renal Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Term Study ◽  
Long Term Study ◽  
Type 2 Diabetic ◽  
Captopril Treatment

scholarly journals Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis

PeerJ ◽  
2017 ◽  
Vol 5 ◽  
pp. e3405 ◽  
Author(s):  
Lubin Xu ◽  
Yang Li ◽  
Jiaxin Lang ◽  
Peng Xia ◽  
Xinyu Zhao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Diabetic Patients ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Type 2 Diabetic Patients ◽  
Sglt2 Inhibition ◽  
Type 2 Diabetic

Aim To evaluate the effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes. Methods We conducted systematic searches of PubMed, Embase and Cochrane Central Register of Controlled Trials up to June 2016 and included randomized controlled trials of SGLT2 inhibitors in adult type 2 diabetic patients reporting estimated glomerular filtration rate (eGFR) and/or urine albumin/creatinine ratio (ACR) changes. Data were synthesized using the random-effects model. Results Forty-seven studies with 22,843 participants were included. SGLT2 inhibition was not associated with a significant change in eGFR in general (weighted mean difference (WMD), −0.33 ml/min per 1.73 m2, 95% CI [−0.90 to 0.23]) or in patients with chronic kidney disease (CKD) (WMD −0.78 ml/min per 1.73 m2, 95% CI [−2.52 to 0.97]). SGLT2 inhibition was associated with eGFR reduction in short-term trials (WMD −0.98 ml/min per 1.73 m2, 95% CI [−1.42 to −0.54]), and with eGFR preservation in long-term trials (WMD 2.01 ml/min per 1.73 m2, 95% CI [0.86 to 3.16]). Urine ACR reduction after SGLT2 inhibition was not statistically significant in type 2 diabetic patients in general (WMD −7.24 mg/g, 95% CI [−15.54 to 1.06]), but was significant in patients with CKD (WMD −107.35 mg/g, 95% CI [−192.53 to −22.18]). Conclusions SGLT2 inhibition was not associated with significant changes in eGFR in patients with type 2 diabetes, likely resulting from a mixture of an initial reduction of eGFR and long-term renal function preservation. SGLT2 inhibition was associated with statistically significant albuminuria reduction in type 2 diabetic patients with CKD.

scholarly journals The effect of HIV infection on glycaemia and renal function in type 2 diabetic patients

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0199946 ◽  
Author(s):  
Siyabonga P. Khoza ◽  
Nigel J. Crowther ◽  
Sindeep Bhana
Keyword(s):  
Renal Function ◽  
Hiv Infection ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Diabetic retinopathy and renal function in Chinese type 2 diabetic patients

2014 ◽  
Vol 46 (7) ◽  
pp. 1375-1381 ◽  
Author(s):  
Huiyan Zhang ◽  
Jianyong Wang ◽  
Gui-shuang Ying ◽  
Liping Shen ◽  
Zhe Zhang
Keyword(s):  
Renal Function ◽  
Diabetic Retinopathy ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Long-Term Oral L-Arginine Administration Improves Peripheral and Hepatic Insulin Sensitivity in Type 2 Diabetic Patients

Diabetes Care ◽  
2001 ◽  
Vol 24 (5) ◽  
pp. 875-880 ◽  
Author(s):  
P. Piatti ◽  
L. D. Monti ◽  
G. Valsecchi ◽  
F. Magni ◽  
E. Setola ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Hepatic Insulin Sensitivity ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document